2020sek
2,1 %
Date:2026-10-14Time:11:33:39Latest report:Q2-2026List:First NorthTicker:GENO
Market Cap:1 363 msekEnterprise Value:1 279 msekNet Sales:135,6 msekEarnings:20,5 msekEmployees:0ISIN:SE0002485979

Ratios

10-year key figure history for Genovis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Genovis with index and moving average MA50 and MA200.

Stockprice:19,98
MA50:20,07
MA200:19,55
Price/MA200:2,6 %
RSI (14):53,3
Price/MA50:-0,1 %

Description

Genovis delivers biotechnology tools and technology platforms to the life sciences and pharmaceutical industries. The company develops enzyme and inhibitor technologies that facilitate, or are integral parts of, a wide range of processes from basic research to pharmaceutical manufacturing and diagnostics. The company operates on a global scale, with customers primarily in North America, Europe and East Asia. Genovis was founded in 1999 and is headquartered in Kävlinge.

Biotechnology